SQZ Biotechnologies Company

OTCPK:SQZB Stock Report

Market Cap: US$884.7k

SQZ Biotechnologies Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure3.1yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

Jun 26
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Jan 05
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

Nov 09

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Oct 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Aug 20
Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

Aug 04

SQZ Biotechnologies names business chief as CFO

Jul 11

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

May 17
Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

May 02
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Jan 11
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Jul 30
Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

May 16
Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

Mar 25
Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 20
SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Feb 01
We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

CEO

SQZ Biotechnologies has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Knopf
General Counsel & Secretary5.4yrsUS$944.03k0.0066%
$ 58.1
Marshelle Warren
Chief Medical Officer2.7yrsUS$944.27k0%
$ 0
Robert S. Langer
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ipsita Roymoulik
Senior Vice President of CMC & QUALITY3.1yrsno datano data

3.1yrs

Average Tenure

62yo

Average Age

Experienced Management: SQZB's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert S. Langer
Co-Founder & Member of Scientific Advisory Boardno datano datano data
David Sachs
Member of Scientific Advisory Boardno datano datano data
Amy W. Schulman
Directorno dataUS$104.40k0.74%
$ 6.6k
Patrick V. J. Vink
Independent Director3.6yrsUS$96.62k0%
$ 0
Klavs Jensen
Independent Director11.9yrsUS$89.40k1.15%
$ 10.2k
Bernard Coulie
Independent Chairman3.6yrsUS$94.40k0%
$ 0
Marc Elia
Independent Director6.8yrsUS$86.90k0%
$ 0
Darrell Irvine
Member of Scientific Advisory Boardno datano datano data
Pushkal Garg
Independent Director6.5yrsUS$94.40k0%
$ 0
Marc Schegerin
Independent Director4.3yrsUS$94.40k0%
$ 0
Arlene Sharpe
Member of Scientific Advisory Boardno datano datano data
Ulrich Andrian
Member of Scientific Advisory Boardno datano datano data

5.4yrs

Average Tenure

61yo

Average Age

Experienced Board: SQZB's board of directors are considered experienced (5.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 15:12
End of Day Share Price 2025/02/06 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SQZ Biotechnologies Company is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Leah Rush CannBrookline Capital Markets
Thomas ShraderBTIG